Chantix, ED drug Web sites, drive most consumer Rx requests: study

Share this article:

Web sites for Pfizer's smoking cessation drug Chantix, erectile dysfunction drugs Cialis, marketed by Lilly and Pfizer's Viagra were the top three online branded pharma product portals driving offline consumer prescription requests, a new study shows.

The product site rankings were based on an online consumer research study of 5,112 US adults conducted by market research firm Manahattan Research.

“Having the most unique visitors is no longer the ultimate goal of a successful pharmaceutical product site,” said Manhattan Research president Mark Bard in a statement. “Brand teams and agencies are being challenged to demonstrate the economic and strategic value created by these online destinations - beyond the raw number of visitors or page views.”

Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests

      1.  Pfizer's Chantix
      2.  Lilly's Cialis
      3.  Pfizer's Viagra
      4.  Eisai and Ortho-McNeil's Aciphex
      5.  Sanofi-Aventis' Ambien CR
      6.  GlaxoSmithKline's Levitra
      7.  Novartis' Lamisil
      8.  Sepracor's Lunesta
      9.  GlaxoSmithKline's Wellbutrin XL
    10.  Ortho-McNeil's Ortho Evra

  -courtesy of Manhattan Research

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.